Company intelligence / Profile preview

Urosphere

Toulouse, Occitanie, Franceurosphere.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Urosphere has supported over 150 biotech/pharma companies with more than 400 compounds through preclinical development using proprietary models of urogenital and related diseases. Their platforms include patient-derived xenografts and organoids to support oncology drug discovery. They have presented at major scientific meetings on the use of their models to study resistance mechanisms and combination therapies in urothelial cancer.

Therapeutic areas: Men's HealthOncologyGastroenterologyNephrologyWomen's Health
Modalities: Small moleculeBiologicAntibody-drug conjugateOrganoid-based therapy/modelingPatient-derived xenograft model systems
Industry: Drug Discovery Services

Partnerships

Over 150 biotech/pharma companiesClinique Urologique Nantes–Atlantis

Beyond the preview

Go deeper on Urosphere.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Urosphere.

Explore the full profile